ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses synovial VEGF and bFGF gene expression. J Rheumatol 2008;35:2119- 28).
Results from treatment studies in a preclinical model of established
rheumatoid arthritis demonstrated that daily oral administration of 2ME2
suppressed both clinical and radiographic indicators of joint inflammation
and damage, including soft tissue swelling and bone erosion. The treatment
benefits of 2ME2 were dose-dependent and associated with reduced joint
expression of the prominent angiogenic growth factors, FGF-2 and VEGF, as
well as decreased angiogenesis. The report further demonstrates both a
delay in onset and decrease in severity of arthritis if 2ME2 treatment is
started prior to disease initiation. These results indicate that 2ME2 may
represent a novel agent for treatment of inflammatory autoimmune diseases
such as rheumatoid arthritis and identify 2ME2 as a disease mod
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved